BIT
VIRX

BlackRock Institutional Trust’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

BlackRock Institutional Trust’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$277K Hold
2,189
– – ﹤0.01% 3551
2016
Q3 		$335K Hold
2,189
– – ﹤0.01% 3559
2016
Q2 		$252K Hold
2,189
– – ﹤0.01% 3605
2016
Q1 		$248K Hold
2,189
– – ﹤0.01% 3582
2015
Q4 		$413K Buy
2,189
+394
+22% +$73.7K ﹤0.01% 3542
2015
Q3 		$305K Buy
1,795
+1,691
+1,626% +$610K ﹤0.01% 3582
2015
Q2 		$66K Sell
104
-2,306
-96% -$1.23M ﹤0.01% 3762
2015
Q1 		$1.24M Buy
2,410
+237
+11% +$120K ﹤0.01% 3281
2014
Q4 		$1.16M Sell
2,173
-83
-4% -$37.4K ﹤0.01% 3305
2014
Q3 		$3.38M Sell
2,256
-338
-13% -$489K ﹤0.01% 2849
2014
Q2 		$3.55M Buy
2,594
+585
+29% +$679K ﹤0.01% 2933
2014
Q1 		$2.79M Buy
2,009
+372
+23% +$433K ﹤0.01% 3026
2013
Q4 		$1.63M Sell
1,637
-181
-10% -$187K ﹤0.01% 3241
2013
Q3 		$1.89M Sell
1,818
-325
-15% -$347K ﹤0.01% 3153
2013
Q2 		$2.33M Buy
+2,143
New +$2.39M ﹤0.01% 3007

Other funds holding VIRX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock Institutional Trust's VIRX Position: Q4 2016 in Review

BlackRock Institutional Trust held its Viracta Therapeutics, Inc. Common Stock (VIRX) position steady in Q4 2016 at 2,189 shares worth $277K. The position accounts for ﹤0.01% of the portfolio, ranked #3551.

BlackRock Institutional Trust first reported a position in VIRX in Q2 2013 and has held it in 15 quarters since. The position peaked at $3.55M in Q2 2014. 45 funds tracked by Wall St. Rank hold VIRX as of Q4 2016.

  • BlackRock Institutional Trust held 2,189 shares of Viracta Therapeutics, Inc. Common Stock worth $277K as of Q4 2016.
  • BlackRock Institutional Trust left its Viracta Therapeutics, Inc. Common Stock share count unchanged in Q4 2016.
  • Viracta Therapeutics, Inc. Common Stock made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3551 holding.
  • BlackRock Institutional Trust first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Institutional Trust's Viracta Therapeutics, Inc. Common Stock position peaked at $3.55M in Q2 2014.
  • 45 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.